3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Thoracic Neoplasms
1
Solid Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Diseases
1
Adenocarcinoma
1
Interventions
pembrolizumab
29
Cisplatin
19
Carboplatin
13
Cetuximab
12
Radiotherapy
10
Paclitaxel
9
Surveys and Questionnaires
8
Docetaxel
6
Radiotherapy, Intensity-Modulated
5
Surgical Procedures, Operative
4
Standard of Care
4
130-nm albumin-bound paclitaxel
4
dostarlimab
3
Therapeutics
3
Nivolumab
3
Fluorouracil
3
Cyclophosphamide
3
Chemoradiotherapy
3
Blood Specimen Collection
3
Albumin-Bound Paclitaxel
3
toripalimab
2
nimotuzumab
2
fludarabine
2
durvalumab
2
atezolizumab
2
abemaciclib
2
X-Rays
2
Taxes
2
Radiosurgery
2
Radiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
pralsetinib
×
90 days
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts